Articles On Recce Pharmaceuticals (ASX:RCE)

The ASX200 is trading down around 1.1% with all eleven sectors in the red. Real-estate has fallen the most, down 1.86%, Industrials follow, shedding around 1.7%. Company News BHP BHP Group (ASX: BHP) has fallen 4.5% to $43.19. afte...

Recce Pharma cleared to increase R327’s minimum dose R327 can now be administered at 4,000mg over a fast infusion of 30 minutes ResMed has had a solid Q3   Recce Pharma cleared to increase drug dose Recce Pharmaceuticals (ASX:RCE) says an...

26 Apr 2024 - A snapshot of the stocks on the move, featuring Tamboran Resources (ASX:TBN), Recce Pharmaceuticals (ASX:RCE) and Cooper Metals (ASX:CPM).

Recce Pharma (ASX:RCE) will dose patients with 4g of its R327 intravenous solution to treat UTIs in Phase I/II trials following safety board approval. The move reflects the latest positive step forward for Recce’s UTI clinical program, f...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Albanese govt announces the Future Made in Australia Act Why supporting Australian Made is a win-win game Stockhead reached out to Australian Made CEO, Ben Lazzaro   The ambitiously named Future Made in Australia Act was launched a couple...

The ASX200 closed the day up more than a per cent (1.08%). All sectors bar one finished in the green. Energy fell 1.5 per cent, but Healthcare lead gains, nearly two per cent (1.97%). Telecommunications followed, up 1.7 per cent. In t...

Recce Pharmaceuticals (ASX:RCE), developing a body of anti-infective drugs for Australian and international markets, posted the results of its latest quarterly on Monday. The company wound up March with $8.5M in cash; an increase of arou...

The ASX200 has shed nearly double what futures predicted, trading down 2.05% All 11 sectors are in the red. Discretionary has lost the most so far, down 2.6%. Real Estate follows, down 2.305%, while in Canberra supermarket executives saw...

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards. What it means is its patented manufacturing p...

Research reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=B5AFE2EB-FB5A-92B3-884578A1BADB01D4 -Argo Global Listed...

Recce Pharmaceuticals (ASX:RCE) published a business update highlighting two key developments with the potential to deliver share price upside on Monday. Firstly, Recce is stepping up its trial activities in Australia’s nearest Asian nei...

The ASX200 is trading down around 1.19 per cent, taking a slight respite from yesterday’s all-time high. Most sectors are in the red, IT has dropped the most, down nearly four per cent. Real estate follows and is down around 3.1 per cent...

Recce Pharmaceuticals (ASX:RCE) has successfully obtained its first patent for its flagship anti-infective drug R327 in Israel. The State of Israel Patent Office ticked off on patent #295116 under ‘Patent Family 4.’ The patent expires in...

The ASX200 had a stellar run on Thursday, closing up more than one point ten per cent.  All sectors except healthcare and utilities finished in the green. The financials sector led the pack at close, finishing one and three quarters p...

The ASX200 has run up 1.16 per cent to be trading in record territory at 7,785 points. All sectors, except Healthcare are in the green. Financials lead the gains, up more than 1.6 per cent. Real estate is following closely up about 1.4 p...

Recce Pharmaceuticals (ASX: RCE), who has been pioneering a new class of synthetic anti-infectives, has secured a Trademark Registration for RECCE® by the Canadian Intellectual Property Office. The International Trademark Registration No...

The ASX200 has traded down well over a per cent this morning – performing worse than predicted. All sectors, except Energy and Real Estate, have been in the red, with Materials shedding more than 2 per cent. Utilities is also making smal...

Recce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its RECCE 327 (R237) synthetic antibiotic, which will be used to treat urinary tract infection (UTI) and urosepsis. The four subjects were do...

There was good news for those with property investments today… the median price of a house in Australia has gone up to $933,800 – that’s a rise of $13,400 in just one quarter. Not such good news for those trying to invest in property, as...

Recce Pharmaceuticals (ASX: RCE) (FSE: R9Q) announces the successful dosing of the latest group of human participants with RECCE 327 (R327) Administered intravenously at a rate of 20 minutes and a dosage of 3,000mg RCE last traded at...

The weekend begins after a day of record breaking on the ASX. The ASX200 closed well over a per cent up at 7847 points, after peaking at 7453 points earlier in the session. The All Ordinaries – Australia’s index of the largest 500 compan...

Recce Pharmaceuticals announces the receipt of an AUD$11,178,965 R&D Advance from Endpoints Capital Agreement allows Endpoints, a SEC-registered investment advisor, to capture Recce’s Research and Development (R&D) tax incentive...

Research reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=17DBBDB4-E20C-03AC-A84AF5C456D084E9 -Amaero International ((3DA)) by Re...

ASX closed flat, as Coles-led Staples sector gained Iron ore stocks under pressure as iron ore futures continue to fall Bitcoin now nearly at US$56k   The ASX 200 closed +0.13% higher on Tuesday, as gains in Consumer Staples were offset b...

The ASX200 has been trading fairly flat, having headed down about .2 per cent earlier in the session. The drags have included the Real Estate sector, materials and communications. However, consumer staples has led the day so far, up n...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and dropped into the red. In afternoon trade, the benchmark index is down 0.25% to 7,633.2 points. Four ASX shares that are not letting that hold them back are listed b...

Recce Pharmaceuticals (ASX:RCE) highlights ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at the Murdoch Children’s Research Institute (MCRI), Victoria The collaboration has been crucial in delivering positive...

Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX!   Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h...

Recce Pharmaceuticals’ (ASX:RCE) flagship product is a versatile drug called R327 It can be used as a gel to treat wound infections The company is investigating on patients with Diabetes suffering post-surgery complications Share...

Recce Pharmaceuticals (ASX:RCE) has signed a Memorandum of Understanding with Indonesian organisation PT Etana Biotechnologies to accelerate the development of the Australian company's anti-infective portfolio.

We’re here for day two of the RIU Resurgence conference in Perth, and it’s certainly busy here with investors, brokers and a host of uranium, batteries metals and gold companies too. The ASX200 is trading down more than half a per cent w...

Recce Pharmaceuticals (ASX:RCE) develops anti-infectives for a range of issues and post-surgical complications The company has now won a patent in Canada Its lead drug R327 is both injectable and applicable as a gel Shares last t...

Shortly before Without A Fight crossed the finish line to win the 2023 Melbourne Cup, the Reserve Bank of Australia lifted the cash rate once again – by 25 basis points to 4.35 per cent for November. The decision was in line with expert...

The Reserve Bank of Australia has decided to lift the cash rate again — upping it by 25 basis points to 4.35 per cent for November. It’s the 13th raise in only 16 months and follows the nation’s latest inflation data released just two w...

Recce Pharmaceuticals (ASX:RCE) completes dosing of the first male and female subjects in its UTI/urosepsis clinical trial at the highest concentration of R327 The dosing lasts 15 minutes at 3000mg and was approved by an independent safe...

The ASX200 lifted nearly 0.2 of a per cent by the end of the day’s session, with materials taking a late run to gain .8 of a per cent. Energy also added almost half a per cent.   Cryptocurrency Bitcoin has also jumped almost 10 per cent...

Recce Pharmaceuticals (ASX:RCE) UTI trial using flagship anti-infective R327 has been greenlit to go further The company can now dose patients 3000mg in an IV transfusion of 15 minutes RCE continues to compile safety data around IV...

Recce Pharma moves forward to stronger dose in Phase 1/2 trial EMV is bench testing its 2nd Gen ultra-light weight helmet scanner   Recce Pharma moves forward to higher dosage Synthetic anti-infectives producer, Recce Pharmaceuticals (ASX...

The ASX200 is down nearly 1.2 percent with most sectors in the red. Energy is the only sector making gains, up just over a third of a per cent.   Liontown Resources (ASX:LTR) has taken a dive, now down nearly 30 per cent after raising $3...

Recce Pharmaceuticals (ASX:RCE) winds up the September quarter with $8 million in cash The company has registered a new trademark in Vietnam Recce’s R327 trials continue to support the company’s thesis its flagship anti-infective is...

Sonia Madigan: Recce Pharmaceuticals (ASX:RCE) has raised $11 million to continue developing its late-stage drug candidate, anti-infective, R327. Why did the company raise now? RCE CEO, James Graham, is here to explain. James Graham:...

Recce Pharmaceuticals (ASX:RCE) is fast-tracking the development of its synthetic class of potent anti-infectives, with significant progress being made in FY23 In FY23, the Anti-Infective Research Unit at the Murdoch Children’s Research...

The ASX200 ended the week up just, despite the week’s losses totalling more than one and half per cent. Utilities, energy and materials led the gains, while real estate was today’s worst performer, down almost 1.5 per cent. In the gr...

Whilst the ASX200 has slipped .6 of a per cent, that performance is considerably better than futures suggested.  Real estate and health care are the key drags on the market today, losing almost 1 and a half per cent each, while consumer...

Recce Pharmaceuticals (RCE) completes dosing its male and female subjects in its phase I/II UTI clinical trial with Scientia Research The trial evaluates R327 anti-infective at faster infusion rates of 30 minutes at a dosage of 3000mg, w...

Treatment for infectious diseases continues to pose a significant threat to populations worldwide, with the effectiveness of many anti-infective medications lost to antimicrobial resistance (AMR).  However, in this current era where conc...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=7D2FBF3D-0297-B05B-8F498AF62BD096F8 –AFT Pharmaceuticals ((AFP)) by Edi...

Recce Pharmaceuticals (ASX: RCE), a company developing a new class of synthetic antibiotics, is raising $11 million to boost its research program, bolster manufacturing capabilities and expand further into the US. The Sydney-based company,...

The ASX200 gradually climbed today to gain close to half a per cent. Financials registered the highest gains, up nearly 1.3 per cent With that, the big four banks NAB, CBA, Westpac and ANZ all gained around a per cent. Healthcare, on...